First-Line Erlotinib with or without Chemotherapy for Never or Light Smokers with Advanced Non-Small Cell Lung Cancer (NSCLC)
First-Line Erlotinib with or without Chemotherapy for Never or Light Smokers with Advanced Non-Small Cell Lung Cancer (NSCLC)
Slides from a presentation at ASCO 2010 and transcribed comments from recent interviews with Roy S Herbst, MD, PhD (6/23/10), Corey J Langer, MD (7/2/10) and Mark A Socinski, MD (6/4/10)
Jänne PA et al. Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406. Proc ASCO 2010;Abstract 7503.
|
||||||||